Ujvira 100 (Trastuzumab emtansine Vials) 100mg

Ujvira 100 (Trastuzumab emtansine) is an injectable medication used in cancer therapy. Store between 2-8°C to maintain potency. This 100mg vial is designed for intravenous use under medical supervision. Always consult a healthcare professional before use.

Strength

100mg

Pack Size

Storage

2-8°

Manufacturer / TM Owner

Cadila Healthcare Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Trastuzumab emtansine, the active ingredient in Ujvira 100, is used to treat certain types of breast cancer and other HER2-positive cancers. It works by targeting cancer cells while limiting damage to healthy cells. This medication is typically prescribed after other treatments have been tried. Patients often ask, what is trastuzumab emtansine used for, and it is primarily indicated for metastatic breast cancer.

Side Effects

Ujvira 100 is administered via infusion, and patients may experience fatigue, nausea, or headaches afterward. Some individuals report mild pain or redness at the injection site. These effects are generally temporary and vary by patient. Always report persistent or severe reactions to a healthcare provider.

Precautions & Warnings

Keep Ujvira 100 refrigerated between 2-8°C and protect from light. Do not freeze or shake the vial. Before using, inspect for particles or discoloration; discard if either is present. Always handle with care and follow local guidelines for cytotoxic drug disposal.

Avoid Interactions

Ujvira 100 may interact with other medications, including CYP3A4 inhibitors or inducers, which can affect its effectiveness. Patients should inform their doctor about all prescription, over-the-counter, and herbal products they are using. Avoid alcohol and live vaccines during treatment unless approved by a healthcare professional.

References

Frequently Asked Questions

Ujvira 100 is used to treat HER2-positive metastatic breast cancer in patients who have previously received other treatments.

It is given as an intravenous infusion by a healthcare professional, typically in a clinical setting.

Ujvira 100 is a prescription medication and should only be purchased through licensed pharmacies or healthcare providers.

Common side effects include fatigue, nausea, headaches, and mild pain at the injection site.

Store Ujvira 100 vials between 2-8°C and protect from light; do not freeze or shake.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.